Roche Annual General Meeting 2020

• All proposals of the Board of Directors approved
• Christoph Franz confirmed as Chairman of the Roche Board of Directors; all other Board members standing for re-election confirmed; Jörg Duschmalé and Patrick Frost elected as new members of the Board of Directors
• Andreas Oeri and Sir John Bell step down from the Board of Directors after 24 and 19 years, respectively
• 33rd consecutive dividend increase to CHF 9.00 per share
  
  

Basel, 17 March 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM).
On the basis of COVID-19 Ordinance 2 of the Swiss Federal Council, no shareholders were admitted to attend the General Meeting in person. Roche had already recommended on March 10 that shareholders should delegate their votes to the independent proxy. The independent proxy represented 85.47 % of the total 160,000,000 shares. The Management Report, the Financial Statements and the Consolidated Financial Statements for 2019 were approved.

Shareholders endorsed the total amount of bonuses paid to the Corporate Executive Committee for 2019 with 99.69 % of the votes, as well as the bonus paid to the Chairman of the Board of Directors for 2019, which was approved by 99.03 % of the votes. Shareholders also authorised the ratification of the Board of Directors’ actions.

Shareholders approved the proposed appropriation of available earnings with 100 % of the votes and approved an increase in the dividend for the past financial year to 9.00 Swiss francs (gross) per share and non-voting equity security. This is the 33rd consecutive dividend increase.
Christoph Franz was confirmed as Chairman of the Board of Directors with 99.52% of the votes.

“2019 was a very good year for Roche. We made further significant progress in renewing our product portfolio. The new medicines are not only driving sales for Roche, they are also making substantial contributions to improving the lives of patients worldwide. The acquisition of Spark Therapeutics adds gene therapy to our portfolio of therapeutic approaches,” said Christoph Franz, Chairman of Roche's Board of Directors. “I am confident that we are well positioned for the future by virtue of our broad portfolio and innovative strength, and that we will continue to make important contributions to the health of people throughout the world.”